Improving Protection against Influenza and Other Respiratory Pathogens: the US Flu VE Network
🏛 Centers for Disease Control and Prevention - ERA (HHS-CDC-HHSCDCERA)
✓ Free, no account · Source: Grants.gov · Last verified Jul 28, 2026
Can you apply?
This grant is for organizations conducting influenza and respiratory pathogen vaccine effectiveness research and surveillance. Eligible applicants must have institutional capacity for active enrollment, respiratory pathogen testing, and longitudinal data collection. Component A focuses on vaccine effectiveness surveillance; Component B provides coordination and surge capacity support. Previous CDC funding recipients and established research institutions with epidemiologic expertise are competitive. Work must align with CDC surveillance and vaccine effectiveness objectives.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Jul 28, 2026 Applications open
- Dec 31, 2026 Application deadline in 155 days
- Aug 31, 2027 Award announced
- Sep 30, 2027 Project start
Program description
The purpose of this notice of funding opportunity (NOFO) is to continue the work of the US Influenza Vaccine Effectiveness (Flu VE) Network. Influenza and other respiratory pathogens are important causes of morbidity, mortality, and healthcare burden across the age spectrum. This network provides evidence needed to improve the effectiveness of influenza and other respiratory pathogen vaccines. You would propose work under this NOFO to include: 1) annual VE and correlates of protection surveillance from active enrollment and systematic respiratory pathogen testing of outpatients; 2) electronic acute respiratory illness and VE surveillance; 3) household transmission research studies; and 4) immunogenicity research studies.
This is a multi-component NOFO of Component A, B, C and D. The anticipated award number for each component is: five for Component A (VE and correlates of protection), one for Component B (Coordination and surge capacity), two for Component C (Household transmission studies) and three for Component D (Immunogenicity studies). You are required to apply for either Component A (VE and correlates of protection) or B (Coordination and surge capacity) but not both. If you apply for Component A, you may also apply for optional Components C (Household transmission studies) or D (Immunogenicity studies) or both. If you apply for Component B, you may also apply for optional Component D.
We expect to fund 5 sites for Component A up to $1,800,000 per site annually and 1 site for Component B up to $1,800,000 annually. Up to 2 sites selected for Component A may be awarded optional Component C to be funded up to $1,00,000 per site annually. Up to 3 sites selected for either Components A or B may be awarded optional Component D to be funded up to $750,000 per site annually.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Application for Federal Assistance)
- Project Narrative
- Budget and Budget Justification
- Organizational Capacity and Infrastructure documentation
- Letters of support from partner health systems or clinics
- Curriculum vitae of key personnel
- Data management and quality assurance plan
Program contact
- 👤 Jocelyn Patterson Mosley
- 📧 jpatterson@cdc.gov
- 📞 404-639-6437
Funding track record
Recent awards under CFDA 93.185 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$153,480,721
-
$134,353,547
-
$125,451,446
-
$120,599,685
-
$119,251,553
-
$116,028,010
-
$114,778,489
-
$114,421,750
-
$106,257,202
-
$104,438,072
Top States by Funding
- NY 5 awards $259.4M
- TX 3 awards $170.2M
- OR 2 awards $148.5M
- CT 2 awards $139.9M
- DC 4 awards $138.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.185). How funding has trended year over year.
| 2024 | $125,888,137 | |
| 2025 | $97,853,899 | |
| 2026 est. | $51,929,831 |
FAQ
Who can apply for this grant?
Organizations with research infrastructure for respiratory surveillance and vaccine effectiveness studies. This typically includes academic medical centers, health departments, and large healthcare systems. You must have capacity for active patient enrollment and lab testing.
What is the deadline and funding range?
The fixed deadline is December 31, 2026. Component A sites receive up to $1.8M annually; Component B receives up to $1.8M annually. Optional components add $750K–$1M per year.
Do I have to choose a component?
Yes. You must apply for Component A or B (but not both). If applying for A, you may add optional Components C or D. If applying for B, you may add optional Component D only.
What activities are supported?
Annual vaccine effectiveness surveillance, electronic respiratory illness monitoring, household transmission studies, and immunogenicity research. Work focuses on collecting data on vaccine performance across age groups and pathogen types.
Is this competitive?
Yes. Only 5 Component A sites, 1 Component B site, and select optional component sites will be funded. Applications should highlight existing research infrastructure and epidemiologic capacity.
💡 Tips for applicants
- Clearly state which component(s) you are applying for and why your site is suited for that work. Component choice determines your scope and optional opportunities.
- Describe your active enrollment infrastructure and respiratory testing capacity in detail. Reviewers prioritize organizations with proven ability to recruit and retain participants.
- Emphasize existing partnerships with health systems, clinics, or public health agencies. Collaborative networks strengthen surveillance and data collection.
- Include a realistic budget that aligns with your component tier ($1.8M for A/B; $750K–$1M for optional C/D). Ensure costs match proposed staffing and lab activities.
- Address how you will sustain multi-year data collection and manage surge capacity during respiratory pathogen seasons. CDC values continuity and rapid response capability.
⚠️ Common mistakes
Applying for both Component A and B when only one is permitted. Weak description of existing infrastructure or patient enrollment networks. Budgets that do not account for lab testing, data management, or staffing for year-round surveillance.
Similar grants
- OPEN Expanded Surveillance for Pediatric Infectious Diseases — Centers for Disease Control and Prevention - ERA
- OPEN Advancing Outbreak Detection, Notification, and Response Capacity by Implementing 7-1-7 in Partner Countries — Centers for Disease Control-GHC
- OPEN Strengthening Global Health Security by improving public health capacity to detect, notify, and respond to disease outbreaks globally — Centers for Disease Control-GHC
- OPEN RFA-CE-18-000 — Centers for Disease Control and Prevention - ERA
- OPEN Sustaining Global Health Security to protect and improve public health in Kenya — Centers for Disease Control-GHC